ALKEM:NSE:NSE-Alkem Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 5129.25

Change

-29.10 (-0.56)%

Market Cap

USD 616.75B

Volume

0.09M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-21 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+10.70 (+0.72%)

USD 3,520.42B
DIVISLAB:NSE Divi's Laboratories Limited

+19.75 (+0.44%)

USD 1,204.18B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-8.60 (-0.80%)

USD 1,116.46B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+23.45 (+0.39%)

USD 1,006.15B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-10.00 (-0.35%)

USD 958.22B
MANKIND:NSE Mankind Pharma Ltd

-36.80 (-1.70%)

USD 877.19B
LUPIN:NSE Lupin Limited

-7.90 (-0.50%)

USD 711.68B
AUROPHARMA:NSE Aurobindo Pharma Limited

-0.70 (-0.06%)

USD 706.45B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-6.50 (-0.53%)

USD 347.26B
AJANTPHARM:NSE Ajanta Pharma Limited

+2.15 (+0.09%)

USD 294.04B

ETFs Containing ALKEM:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.18% 34% F 34% F
Dividend Return 0.68% 47% F 56% F
Total Return 0.86% 35% F 35% F
Trailing 12 Months  
Capital Gain 53.11% 58% F 58% F
Dividend Return 1.34% 83% B 68% D+
Total Return 54.46% 58% F 58% F
Trailing 5 Years  
Capital Gain 191.36% 54% F 53% F
Dividend Return 8.24% 78% C+ 64% D
Total Return 199.60% 55% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 22.30% 36% F 34% F
Dividend Return 23.24% 37% F 35% F
Total Return 0.94% 76% C+ 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 23.97% 88% B+ 84% B
Risk Adjusted Return 96.96% 86% B+ 86% B+
Market Capitalization 616.75B 90% A- 92% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.